

Sample	Age/Sex	Leukemia classification and phenotype	Sorting marker
LAA	61/F	AML M0; >90% blasts, normal cytogenetics; positive for CD13, 33, 34, 45, 117, 11b, HLA-DR, MPO; dim positive for CD42a, 2, 19; negative for CD10	CD34+
AGM	62/M	AML M1; 94% blasts, normal cytogenetics; positive for HLA-DR, CD34, 45, 117; dim positive for CD13, CD33, CD19; negative for CD42a, 2, 11b	CD34+
MFSS	36/F	AML M1; 99% blasts, normal cytogenetics; positive for CD13, CD33, CD34, CD45, CD117; dim positive for HLA-DR, CD11b; negative for CD2, 19, 42a	CD34+ and CD33+
JCS	40/M	AML M1; 98% blasts; positive for CD13, 33, 34, 45, 11b, 19; dim positive for HLA-DR; negative for TdT, CD42a, 2, 10	CD34+ and CD33+
DC	15/M	AML M1; 94% blasts; positive for CD13, 33, 34, 45, 117, 2, 11b, HLA-DR; negative for CD19, 42a	CD34+ and CD33+
OAM <sup>a</sup>	33/M	AML M1; 94% blasts; positive for CD13, 33, 34, 45, 117, 15, 2, 11b, TdT, HLA-DR; negative for CD19, 42a, 14, 56	CD34+ and CD33+
EMB	16/M	AML M1; 94% blasts; positive for CD13, 33, 34, 45, 117, HLA-DR; dim positive for CD2, 11b; negative for CD42a, 19	CD34+ and CD33+
ERR	53/F	AML M1; 98% blasts; positive for CD13, 33, 34, 45, 117, MPO, CD11b; dim positive for HLA-DR, CD2; negative for CD19, 42a, 10	CD34+ and CD33+
UPN21	16/F	AML; wbc (white blood cell) 287.5 k/ $\mu$ L, hgb (haemoglobin) 7.3 g/dL, plt (platelet) 18 k/ $\mu$ L; 81% blasts, 6% lymphs (lymphocytes), 1% meta (metamyelocytes), 11% monos (monocytes); positive for CD33, 13, 117, 52, 34, HLA-DR	CD34+; CD33+
UPN1	47/F	AML M2; wbc 169 k/ $\mu$ L, hgb 11 g/dL, plt 116 k/ $\mu$ L; 90% blast; positive for CD33, 13	CD13+ and CD33+
UPN16	74/F	Secondary AML/MDS; wbc 99.7 k/ $\mu$ L, hgb 7.5 g/dL, plt 31 k/ $\mu$ L; 62% blasts; dim positive for CD117; positive for CD34, 13, 33, 9, HLA-DR	CD34+
UPN22	11/F	Relapsed AML; wbc 310 k/ $\mu$ L, hgb 10.5 g/dL, plt 27 k/ $\mu$ L; 85% blasts, 13% lymphs, 1% monos; positive for CD33, 64, HLA-DR; dim positive for MPO; negative for CD34, 117, 14, TdT	CD34+; CD33+
UPN18	62/F	AML & prior non-Hodgkin lymphoma (NHL); wbc 106 k/ $\mu$ L, hgb 7.2 g/dL, plt 10 k/ $\mu$ L; 60% blasts; Positive for CD117, 33, 45; dim positive for CD34, 11b, 14, MPO and HLA-DR; negative for CD10, 20, 56, 2, 7, TdT, 64	CD34+

UPN20	53/M	CML-blast crisis stage; wbc 135.8 k/ $\mu$ L, hgb 9.3 g/dL, plt 319 k/ $\mu$ L; 52% blasts, 22% segs (neutrophils), 9% lymphs, 9% monos; positive for CD34, 33, 13, 9, 5, 38, 56, HLA-DR; negative for MPO, TdT; dim for CD41, 117	CD34+; CD33+
UPN17	27/F	CML-chronic phase; wbc 165 k/ $\mu$ L, hgb 9.6 g/dL, plt 308 k/ $\mu$ L; 0% blasts, 75%segs	CD34+
UPN2	58/M	Acute leukemia from CMML; wbc 209 k/ $\mu$ L, hgb 8.8 g/dL, plt 55 k/ $\mu$ L; 86% blast; positive for CD33, 34	CD33+ and CD34+
UPN3	64/F	T prolymphocytic CLL; wbc 157 k/ $\mu$ L; 90% blast; positive for CD5; negative for CD33	CD5+ and CD33-
UPN19	21/F	Microgranular variant APLM; wbc 87.4 k/ $\mu$ L, hgb 9.2 g/dL, plt 12 k/ $\mu$ L; 71% blasts, 10% segs, 9% lymphs; positive for CD117, 33, 13, MPO; negative for CD14, 34, 19, 64, HLA-DR	CD34+; CD33+; CD33+ and CD34-

Note: Subtypes (M0, M1, and M2) of acute myeloid leukemia (AML) were defined according to the French-American-British (FAB) classification. CML – chronic myelogenous leukemia, APLM – acute promyelocytic leukemia, CMML – chronic myelomonocytic leukemia, CLL – chronic lymphocytic leukemia, MDS – myelodysplastic syndrome.

<sup>a</sup> We also collected a sample for this patient during relapse; cell surface markers of blasts were the same as at diagnosis.